Document:

Exhibit 4.1

 

Execution

 

NEITHER THIS SECURITY
NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON STOCK PURCHASE WARRANT

 

HealthLynked Corp.

 

	Warrant Shares: 3,846,154	Issue Date: February 26, 2021

 

THIS COMMON STOCK PURCHASE
WARRANT (the “Warrant”) certifies that, for value received, DanKris1, LLC, or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the date hereof (the “Issue Date”) and on or prior to 5 PM New York City Time on February 25, 2026
(the “Termination Date”) but not thereafter, to subscribe for and purchase from HealthLynked Corp., a Nevada
corporation (the “Company”), up to 3,846,154 shares (as subject to adjustment hereunder, the “Warrant
Shares”) of the common stock of the Company, par value $0.0001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed (“Common Stock”). The purchase price of one share of
Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b).

 

Section 1Exercise.

 

a) Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Issue Date and on or before the Termination Date by delivery to the Company (or such other office or agency of
the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books
of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed hereto and
within five (5) Trading Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received payment
of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check drawn on a United States
bank or pursuant to the cashless exercise procedure specified in Section 1(c) below. No ink-original Notice of Exercise shall be
required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which
case, the Holder shall, upon written request, surrender this Warrant to the Company for cancellation within five (5) Trading Days
of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number
of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise, in writing, within one (1) Business Day of receipt of such notice. The Holder
and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof.

 

    1

     

    

 

b) Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall initially be $0.42, subject to adjustment
hereunder (the “Exercise Price”).

 

c) Cashless
Exercise. If at any time after the six month anniversary of the Issue Date, there is no effective Registration Statement registering,
or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may be exercised, in
whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a
number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

(A) = the
VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless
exercise,” as set forth in the applicable Notice of Exercise;

 

(B) = the
Exercise Price of this Warrant, as adjusted hereunder; and

 

(X) =
the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period
of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares.  The Company agrees not
to take any position contrary to this Section 1(c).

 

“Trading
Day” shall mean a day on which there is trading or quoting for any security on the Company’s principal Trading
Market.

 

    2

     

    

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading
on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if the Common Stock is not then listed or
quoted for trading on a Trading Market and if prices for the Common Stock are then reported in the “Pink Sheets” published
by OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid
price per share of the Common Stock so reported, or (c) in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.

 

Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 1(c).

 

d)
Mechanics of Exercise.

 

i. Delivery
of Warrant Shares Upon Exercise. Warrant Shares purchased hereunder shall be transmitted by the Company’s transfer agent
(the “Transfer Agent”) to the Holder by crediting the account of the Holder’s or its designee’s
balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”)
if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the
issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale
by the Holder without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of a certificate,
registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to
which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the
date that is five (5) Trading Days after the delivery to the Company of the Notice of Exercise (such date, the “Warrant
Share Delivery Date”). The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated
to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant
has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required
to be paid by the Holder, if any, pursuant to Section 1(d)(vi) prior to the issuance of such shares, having been paid.

 

    3

     

    

 

ii. Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the un-purchased Warrant Shares called for by this Warrant, which new Warrant shall in all
other respects be identical with this Warrant.

 

iii. Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 1(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv. No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

v. Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The
Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery
of the Warrant Shares.

 

vi. Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.

 

    4

     

    

 

e) Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, to the extent that after giving effect to such issuance after exercise as set forth on the applicable
Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with
the Holder or any of the Holder’s Affiliates, any and all such Persons are referred to herein as “Attribution Parties”),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of the foregoing
sentence, the number of shares of Common Stock beneficially owned by the Holder and the Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall
exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, non-exercised portion
of this Warrant beneficially owned by the Holder or any of the Attribution Parties and (ii) exercise or conversion of the unexercised
or non-converted portion of any other securities of the Company (including, without limitation, any other Common Stock equivalents)
subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder
or any of the Attribution Parties.  Except as set forth in the preceding sentence, for purposes of this Section 1(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with
Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this Section 1(e) applies, the determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership
Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination
as to any group status as contemplated above shall be determined in accordance with Section 1(d) of the Exchange Act and the rules
and regulations promulgated thereunder. For purposes of this Section 1(e), in determining the number of outstanding shares of Common
Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent
periodic or annual report filed with the SEC, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. 
Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall
be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon at least 61 days’
notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 1(e), provided that
the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 1(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the
61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section 1(e) to correct this paragraph (or any portion hereof)
which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or
supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall
apply to a successor holder of this Warrant. For purposes of this Warrant, “Affiliate” means any Person that,
directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person,
as such terms are used in and construed under Rule 405 under the Securities Act.

 

    5

     

    

 

Section 2Certain
Adjustments.

 

a) Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 2(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b) Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 2(a) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such
extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase
Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the Beneficial Ownership Limitation).

 

c) Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "Distribution"),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in
such Distribution (provided, however, to the extent that the Holder's right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if
ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

    6

     

    

 

d) Calculations.
All calculations under this Section 2 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 2, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

e) Notice
to Holder.

 

i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 2, the Company shall promptly
mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of
Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii. Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or
effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the
date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or
close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale,
transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall
not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided
in this Warrant constitutes, or contains, material, non-public information regarding the Company, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this
Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except
as may otherwise be expressly set forth herein.

 

    7

     

    

 

Section 3Transfer
of Warrant.

 

a) Transferability.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 3(d) hereof, this Warrant and
all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company
or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed
by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name
of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment,
and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly
be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall, upon written request, surrender
this Warrant to the Company within five (5) Trading Days of the date the Holder delivers an assignment form to the Company assigning
this Warrant full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase
of Warrant Shares without having a new Warrant issued.

 

b) New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 3(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original
Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c) Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.

 

d) Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and
under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or
current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer,
that the Holder or transferee of this Warrant, as the case may be, make usual and customary representations as to investment intent
to the Company.

 

    8

     

    

 

e) Representation
by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any
exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for
distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.

 

Section 4Miscellaneous.

 

a) No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 1(d)(i), except as expressly set forth in
Section 2.

 

b) Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of
such Warrant or stock certificate.

 

c) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day. For purposes of this Warrant, “Business Day” means any day other than Saturday, Sunday or other
day on which commercial banks in The City of New York are authorized or required by law to remain closed; provided, however, for
clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to “stay at
home”, “shelter-in-place”, “non-essential employee” or any other similar orders or restrictions or
the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer
systems (including for wire transfers) of commercial banks in The City of New York are generally are open for use by customers
on such day.

 

d) Authorized
Shares.

 

The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and non-assessable and free from all taxes, liens and charges created
by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).

 

    9

     

    

 

Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this
Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public
regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.

 

e) Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the laws of the State of New York, without regard to New York’s conflict of laws principles.

 

f) Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and if the Holder
does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g) Non-waiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date. If the Company fails to comply with any provision of this Warrant, which results
in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

    10

     

    

 

h) Notices.
Any notice, request or other document required or permitted to be given or delivered to the either party to the other shall be
delivered in by recognized overnight courier, facsimile or email as follows:

 

If
to the Investor: Email: Daniel.hall@krisdan.com

 

		If to the
                              Company:	HealthLynked
                                         Corp.

1265
Creekside Parkway Suite 302

Naples,
FL 34108

Attn:
George O'Leary

Email:
goleary@healthlynked.com

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.

 

j) Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.

 

k) Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

l) Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

m) Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.

 

********************

 

[Signature Page
to Follow.]

 

    11

     

    

 

IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

	 	HealthLynked Corp.
	 	 
	 	By:	                              
	 	 	George O’Leary CFO

 

    12

     

    

 

NOTICE OF EXERCISE

 

		To:	HealthLynked
Corp.

 

(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.

 

(2) Payment
shall take the form of (check applicable box):

 

☐ in lawful
money of the United States; or

 

☐ if permitted
the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in Section 1(c), to
exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in Section 1(c).

 

(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

The Warrant Shares shall be delivered to
the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4) Accredited Investor.
The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933,
as amended.

 

[SIGNATURE
OF HOLDER]

 

Name of Investing Entity: ______________________________________________

 

Signature of Authorized Signatory of
Investing Entity: ________________________

 

Name of Authorized Signatory: __________________________________________

 

Title of Authorized Signatory: ___________________________________________

 

Date: ___________________________________________________

 

    13

     

    

 

ASSIGNMENT
FORM

 

(To assign the
foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED,
the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	
        

        Name:
	 	
	 	 	(Please Print)
	 	 	 
	Address:	 	
	 	 	 
	 	 	(Please Print)
	Dated: _______________ __, ______	 	 
	 	 	 
	Holder’s Signature:                                    	 	 
	 	 	 
	Holder’s
                                                     Address:                                      
	 	 

 

 

14Exhibit 10.1

 

Execution

 

Subscription Agreement

 

THE SECURITIES HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION. THERE ARE FURTHER
RESTRICTIONS ON THE TRANSFERABILITY OF THE SECURITIES DESCRIBED HEREIN.

 

THE PURCHASE OF THE
SECURITIES INVOLVES A HIGH DEGREE OF RISK AND SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN BEAR THE RISK OF THE LOSS OF THEIR ENTIRE
INVESTMENT.

 

HEALTHLYNKED CORP.

1265
Creekside Parkway Suite 302

Naples,
Florida 34108

 

Ladies and Gentlemen:

 

The undersigned understands
that HEALTHLYNKED CORP., a corporation organized under the laws of Nevada (the "Company"), is offering an aggregate
of 7,692,308 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”),
and warrants to purchase 3,846,154 shares of Common Stock (the “Warrants”, and together with the Shares, the
"Securities") in a private placement. The undersigned further understands that the offering is being made without
registration of the Securities under the Securities Act of 1933, as amended (the "Securities Act"), or any securities
law of any state of the United States or of any other jurisdiction, and is being made only to "accredited investors"
(as defined in Rule 501 of Regulation D under the Securities Act).

 

1. Subscription.
Subject to the terms and conditions hereof, the undersigned hereby irrevocably subscribes for the Securities set forth in Appendix
A hereto for the aggregate purchase price set forth in Appendix A, which is payable as described in Section 4 hereof. The
undersigned acknowledges that the Securities will be subject to restrictions on transfer as set forth in this subscription agreement
(the "Subscription Agreement").

 

2. Acceptance
of Subscription and Issuance of Securities. It is understood and agreed that the Company shall have the sole right, at its
complete discretion, to accept or reject this subscription, in whole or in part, for any reason and that the same shall be deemed
to be accepted by the Company only when it is signed by a duly authorized officer of the Company and delivered to the undersigned
at the Closing referred to in Section 3 hereof. Notwithstanding anything in this Subscription Agreement to the contrary,
the Company shall have no obligation to issue any of the Securities to any person who is a resident of a jurisdiction in which
the issuance of Securities to such person would constitute a violation of the securities, "blue sky" or other similar
laws of such jurisdiction (collectively referred to as the "State Securities Laws").

 

     

    

    

 

3. The
Closing. The closing of the purchase and sale of the Securities (the "Closing" and the date of such Closing,
the “Closing Date”) shall take place at the offices of the Company, at 10:00 a.m. Eastern Time on February 26,
2021 or at such other time and place as the Company may designate by notice to the undersigned.

 

4. Payment
for Securities. Payment for the Securities shall be received by the Company from the undersigned by wire transfer of immediately
available funds or other means approved by the Company at or prior to the Closing, in the amount as set forth in Appendix A hereto.
The Company shall deliver certificates representing the Securities to the undersigned at the Closing bearing an appropriate legend
referring to the fact that the Securities were sold in reliance upon an exemption from registration under the Securities Act.

 

5. Representations
and Warranties of the Company. As of the date hereof and as of the Closing, the Company represents and warrants to the undersigned
that:

 

(a) The
Company is duly formed and validly existing under the laws of Nevada, with full power and authority to conduct its business as
it is currently being conducted and to own its assets; and has secured any other authorizations, approvals, permits and orders
required by law for the conduct by the Company of its business as it is currently being conducted.

 

(b) The
Company has all requisite power and authority to issue and sell the Securities, enter into this Subscription Agreement and to perform
all the obligations required to be performed by it hereunder. The execution and delivery of this Subscription Agreement and the
Common Stock Purchase Warrant evidencing the Warrants (the “Warrant Agreement”) by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby, including, without limitation, the issuance of the Shares and
the Warrants and the reservation for issuance and the issuance of the shares of Common Stock issuable upon exercise of the Warrants
(the “Warrant Shares”) have been duly authorized by the Company’s Board of Directors and no further filing,
consent or authorization is required by the Company, its Board of Directors or its stockholders. This Subscription Agreement and
the Warrant Agreement have been duly executed and delivered by the Company, and constitute the legal, valid and binding obligations
of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability may be
limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar
laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

    2

    

    

 

(c) The
execution, delivery and performance of this Subscription Agreement and the Warrant Agreement by the Company and the
consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance
of the Shares and the Warrants and reservation for issuance and issuance of the Warrant Shares) will not (i) result in a
violation of the Articles of Incorporation (as defined below) or Bylaws (as defined below) or other organizational documents
of the Company, or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would
become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which the Company is a party, or (iii) result in a violation of any law, rule,
regulation, order, judgment or decree (including foreign, federal and state securities laws and regulations and the rules and
regulations of the OTC QB market (the “Principal Market”) and including all applicable foreign, federal, state
laws, rules and regulations) applicable to the Company or by which any property or asset of the Company is bound or
affected.

 

(d) The
issuance of the Shares and the Warrants are duly authorized and, upon issuance in accordance with the terms of this Subscription
Agreement, the Shares and the Warrants shall be validly issued and free from all preemptive or similar rights, taxes, liens and
charges and other encumbrances with respect to the issue thereof and the Shares shall be fully paid and nonassessable with the
undersigned being entitled to all rights accorded to a holder of Common Stock. As of the Closing, a number of shares of Common
Stock shall have been duly authorized and reserved for issuance which equals the maximum number of shares of Common Stock issuable
upon exercise of the Warrants. Upon exercise of the Warrants in accordance with the Warrant Agreement, the Warrant Shares will
be validly issued, fully paid and nonassessable and free from all preemptive or similar rights, taxes, liens, charges and other
encumbrances with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock.
Assuming the accuracy of each of the representations and warranties set forth in Section 6 of this Subscription Agreement,
the offer and issuance by the Company of the Securities is exempt from registration under the Securities Act.

 

(e) Neither
the Company, nor any of its affiliates, nor any person acting on its or their behalf, has engaged in any form of general solicitation
or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Securities. The Company
shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or brokers’ commissions
relating to or arising out of the transactions contemplated hereby. The Company shall pay, and hold the undersigned harmless against,
any liability, loss or expense (including, without limitation, reasonable attorney’s fees and out-of-pocket expenses) arising
in connection with any such claim. The Company has not engaged any placement agent or other agent in connection with the offer
or sale of the Securities.

 

    3

    

    

 

(f) None of the
Company, or any of its affiliates, nor any person acting on their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the
issuance of any of the Securities under the Securities Act, whether through integration with prior offerings or otherwise, or
cause this offering of the Securities to require approval of stockholders of the Company for purposes of the Securities Act
or any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of any
exchange or automated quotation system on which any of the securities of the Company are listed or designated for quotation.
None of the Company, or any of its affiliates, nor any person acting on their behalf will take any action or steps that would
require registration of the issuance of any of the Securities under the Securities Act or cause the offering of any of the
Securities to be integrated with other offerings for purposes of any such applicable stockholder approval provisions.

 

(g) The
Company and its Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition,
interested stockholder, business combination, poison pill (including, without limitation, any distribution under a rights agreement)
or other similar anti-takeover provision under the Articles of Incorporation, Bylaws or other organizational documents or the laws
of Nevada which is or could become applicable to the undersigned as a result of the transactions contemplated by this Subscription
Agreement, including, without limitation, the Company’s issuance of the Securities and the undersigned’s ownership
of the Securities. The Company and its Board of Directors have taken all necessary action, if any, in order to render inapplicable
any stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of Common Stock or a change
in control of the Company.

 

(h) The
authorized capital stock of the Company consists of (i) 500,000,000 shares of Common Stock, of which as of the date hereof, 215,751,019
are issued and outstanding, 11,412,924 shares are reserved for issuance pursuant to the Company’s stock option and purchase
plans and 114,851,736 shares are reserved for issuance pursuant to securities (other than the aforementioned options and Warrants)
exercisable or exchangeable for, or convertible into, Common Stock and (ii) 20,000,000 shares of preferred stock, par value $0.0001
per share, of which 2,750,000 shares are designated as Series B preferred stock, of which 2,750,000 are currently issued and outstanding.
No Common Stock are held in treasury. All of such outstanding shares are duly authorized and have been, or upon issuance will be,
validly issued and are fully paid and nonassessable. None of the Company’s capital stock is subject to preemptive rights
or any other similar rights or any liens or encumbrances suffered or permitted by the Company. Except as disclosed above, there
are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating
to, or securities or rights convertible into, or exercisable or exchangeable for, any capital stock of the Company, or contracts,
commitments, understandings or arrangements by which the Company is or may become bound to issue additional capital stock of the
Company or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities
or rights convertible into, or exercisable or exchangeable for, any capital stock of the Company; (iii) there are no securities
or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities; and (iv)
the Company does not have any stock appreciation rights or “phantom stock” plans or agreements or any similar plan
or agreement. True, correct and complete copies of the Company’s articles of incorporation, as amended and as in effect on
the date hereof (the “Articles of Incorporation”), and the Company’s bylaws, as amended and as in effect on the
date hereof (the “Bylaws”), and the terms of all securities convertible into, or exercisable or exchangeable for, Common
Stock and the material rights of the holders thereof in respect thereto have heretofore been filed as part of the SEC Documents.

 

    4

    

    

 

(i) The Company
has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the
Securities Act and the Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to
Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the
Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and
documents incorporated by reference therein, and the Company’s registration statements on Form S-1 and Form S-8, being
collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension.  As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the
Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading. The financial statements of the Company included in
the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of
the Securities and Exchange Commission (the “Commission”) with respect thereto as in effect at the time of
filing.  Such financial statements have been prepared in accordance with United States generally accepted accounting
principles applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise
specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain
all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company as of and
for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of
unaudited statements, to normal, immaterial, year-end audit adjustments.

 

(j) Since
the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent
SEC Report filed prior to the date hereof, (i) there has been no event, occurrence or development that has had or that could
reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with
past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP
or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the
Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed
or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity
securities to any officer, director or affiliate, except pursuant to existing Company stock option plans.  The Company does
not have pending before the Commission any request for confidential treatment of information.  “Material Adverse
Effect” means (i) a material adverse effect on the legality, validity or enforceability of this Subscription Agreement,
(ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and its subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to
perform in any material respect on a timely basis its obligations under this Subscription Agreement.

 

    5

    

    

 

(k) There is no
action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any subsidiary or any of their respective properties before or by any court,
arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an “Action”).  Neither the Company nor any subsidiary, nor any director or officer
thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state
securities laws or a claim of breach of fiduciary duty.  There has not been, and to the knowledge of the Company, there
is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director
or officer of the Company.  The Commission has not issued any stop order or other order suspending the effectiveness of
any registration statement filed by the Company or any subsidiary under the Exchange Act or the Securities Act.

 

(l) At
the Closing, all stock transfer or other taxes (other than income or similar taxes) which are required to be paid in connection
with the issuance, sale and transfer of the Securities to be sold to the undersigned hereunder will be, or will have been, fully
paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with.

 

6. Representations
and Warranties of the Undersigned. The undersigned hereby represents and warrants to and covenants with the Company that:

 

(a) General.

 

(i) The
undersigned has all requisite authority to purchase the Securities, enter into this Subscription Agreement and to perform all the
obligations required to be performed by the undersigned hereunder, and such purchase will not contravene any law, rule or regulation
binding on the undersigned or any investment guideline or restriction applicable to the undersigned.

 

    6

    

    

 

(ii) The
undersigned is a resident of the state set forth on the signature page hereto and is not acquiring the Securities as a nominee
or agent or otherwise for any other person.

 

(iii) The
undersigned will comply with all applicable laws and regulations in effect in any jurisdiction in which the undersigned purchases
or sells Securities and obtain any consent, approval or permission required for such purchases or sales under the laws and regulations
of any jurisdiction to which the undersigned is subject or in which the undersigned makes such purchases or sales, and the Company
shall have no responsibility therefor.

 

(b) Information
Concerning the Company.

 

(i) The
undersigned has access to and carefully reviewed the Company’s SEC Reports and has had an opportunity for a reasonable period
of time prior to the date hereof to obtain additional information concerning the offering of the Securities, the Company, and all
other information to the extent the Company possesses such information or can acquire it without unreasonable effort or expense.

 

(ii) The
undersigned understands and accepts that the purchase of the Securities involves various risks, including the risks outlined in
the SEC Reports and this Subscription Agreement. The undersigned represents that it is able to bear any loss associated with an
investment in the Securities.

 

(iii) The
undersigned confirms that it is not relying on any communication (written or oral) of the Company or any of its affiliates, as
investment advice or as a recommendation to purchase the Securities. It is understood that information and explanations related
to the terms and conditions of the Securities provided by the Company or any of its affiliates shall not be considered investment
advice or a recommendation to purchase the Securities, and that neither the Company nor any of its affiliates is acting or has
acted as an advisor to the undersigned in deciding to invest in the Securities. The undersigned acknowledges that neither the Company
nor any of its affiliates has made any representation regarding the proper characterization of the Securities for purposes of determining
the undersigned's authority to invest in the Securities.

 

(iv) The
undersigned is familiar with the business and financial condition and operations of the Company, all as generally described in
the SEC Reports. The undersigned has had access to such information concerning the Company and the Securities as it deems necessary
to enable it to make an informed investment decision concerning the purchase of the Securities.

 

(v) The
undersigned understands that, unless the undersigned notifies the Company in writing to the contrary at or before the Closing,
each of the undersigned's representations and warranties contained in this Subscription Agreement will be deemed to have been reaffirmed
and confirmed as of the Closing, taking into account all information received by the undersigned.

 

    7

    

    

 

(vi) The
undersigned acknowledges that the Company has the right in its sole and absolute discretion to abandon this private placement at
any time prior to the completion of the offering. This Subscription Agreement shall thereafter have no force or effect and the
Company shall return the previously paid subscription price of the Securities, without interest thereon, to the undersigned.

 

(vii) The
undersigned understands that no federal or state agency has passed upon the merits or risks of an investment in the Securities
or made any finding or determination concerning the fairness or advisability of this investment.

 

(c) Non-reliance.

 

(i) The
undersigned represents that it is not relying on (and will not at any time rely on) any communication (written or oral) of the
Company, as investment advice or as a recommendation to purchase the Securities.

 

(ii) The
undersigned confirms that the Company has not given any guarantee or representation as to the potential success, return,
effect or benefit (either legal, regulatory, tax, financial, accounting or otherwise) of an investment in the Securities. In
deciding to purchase the Securities, the undersigned is not relying on the advice or recommendations of the Company and the
undersigned has made its own independent decision that the investment in the Securities is suitable and appropriate for the
undersigned.

 

(d) Status
of Undersigned.

 

(i) The
undersigned has such knowledge, skill and experience in business, financial and investment matters that the undersigned is capable
of evaluating the merits and risks of an investment in the Securities. With the assistance of the undersigned's own professional
advisors, to the extent that the undersigned has deemed appropriate, the undersigned has made its own legal, tax, accounting and
financial evaluation of the merits and risks of an investment in the Securities and the consequences of this Subscription Agreement.
The undersigned has considered the suitability of the Securities as an investment in light of its own circumstances and financial
condition and the undersigned is able to bear the risks associated with an investment in the Securities and its authority to invest
in the Securities.

 

(ii) The
undersigned is an "accredited investor" as defined in Rule 501(a) under the Securities Act. The undersigned agrees to
furnish any additional information reasonably requested by the Company or any of its affiliates to assure compliance with applicable
U.S. federal and state securities laws in connection with the purchase and sale of the Securities. Any information that has been
furnished or that will be furnished by the undersigned to evidence its status as an accredited investor is accurate and complete,
and does not contain any misrepresentation or material omission.

 

    8

    

    

 

(e) Restrictions
on Transfer or Sale of Securities. As applies to the undersigned:

 

(i) The
undersigned is acquiring the Securities solely for the undersigned’s own beneficial account, for investment purposes, and
not with a view to, or for resale in connection with, any distribution of the Securities. The undersigned understands that the
Securities have not been registered under the Securities Act or any State Securities Laws by reason of specific exemptions under
the provisions thereof which depend in part upon the investment intent of the undersigned and of the other representations made
by the undersigned in this Subscription Agreement. The undersigned understands that the Company is relying upon the representations
and agreements contained in this Subscription Agreement (and any supplemental information) for the purpose of determining whether
this transaction meets the requirements for such exemptions.

 

(ii) The
undersigned understands that the Securities are "restricted securities" under applicable federal securities laws and
that the Securities Act and the rules of the Commission provide in substance that the undersigned may dispose of the Securities
only pursuant to an effective registration statement under the Securities Act or an exemption therefrom, and the undersigned understands
that other than as set forth in Section 10, the Company has no obligation or intention to register any of the Securities.

 

(iii) The
undersigned agrees: (A) that the undersigned will not sell, assign, pledge, give, transfer or otherwise dispose of the Securities
or any interest therein, or make any offer or attempt to do any of the foregoing, except pursuant to a registration of the Securities
under the Securities Act and all applicable State Securities Laws, or in a transaction which is exempt from the registration provisions
of the Securities Act and all applicable State Securities Laws; (B) that the certificates representing the Securities will bear
a legend making reference to the foregoing restrictions (subject to the legend removal requirements described below); and (C) that
the Company and its affiliates shall not be required to give effect to any purported transfer of such Securities except upon compliance
with the foregoing restrictions.

 

(iv) The
undersigned acknowledges that neither the Company nor any other person offered to sell the Securities to it by means of any form
of general solicitation or advertising, including but not limited to: (A) any advertisement, article, notice or other communication
published in any newspaper, magazine or similar media or broadcast over television or radio or (B) any seminar or meeting whose
attendees were invited by any general solicitation or general advertising.

 

    9

    

    

 

7. Conditions
to Obligations of the Undersigned and the Company. The obligations of the undersigned to purchase and pay for the Securities
specified in Appendix A and of the Company to sell the Securities are subject to the satisfaction at or prior to the Closing of
the following conditions precedent: the representations and warranties of the Company contained in Section 5 hereof and
of the undersigned contained in Section 6 hereof shall be true and correct as of the Closing in all respects with the same
effect as though such representations and warranties had been made as of the Closing.

 

8. Obligations
Irrevocable. The obligations of the undersigned shall be irrevocable.

 

9. Legend.
The certificates representing the Securities sold pursuant to this Subscription Agreement will be imprinted with a legend in substantially
the following form:

"THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR THE SECURITIES LAWS OF ANY STATE
OR OTHER JURISDICTION. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (1) PURSUANT TO AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OR (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, IN
EACH CASE IN ACCORDANCE WITH ALL APPLICABLE STATE SECURITIES LAWS AND THE SECURITIES LAWS OF OTHER JURISDICTIONS, AND IN THE CASE
OF A TRANSACTION EXEMPT FROM REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT
THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH OTHER APPLICABLE LAWS."

 

The legend set forth
above shall be removed and the Company shall issue certificates without such legend to the holder of the Securities upon which
it is stamped or issue to such holder by electronic delivery at the applicable balance account at The Depository Trust Company
(“DTC”), if (i) such Securities are registered for resale under the Securities Act, (ii) in connection with a sale,
assignment or other transfer, such holder provides the Company with an opinion of counsel, in a generally acceptable form, to the
effect that such sale, assignment or transfer of the Securities may be made without registration under the applicable requirements
of the Securities Act, or (iii) the Securities can be sold, assigned or transferred pursuant to Rule 144. The Company shall be
responsible for the fees of its transfer agent and all DTC fees associated with such issuance.

 

    10

    

    

 

10. Piggy-Back
Registrations. If, at any time following Closing, there is not an effective registration statement covering all of the Shares
and Warrant Shares and the Company shall determine to prepare and file with the Commission a registration statement relating to
an offering for its own account or the account of others under the Securities Act of any of its equity securities (a “Piggyback
Registration Statement”), other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their
then equivalents or any other registration statement relating to equity securities issued solely in connection with any acquisition
of any entity or business as acquisition consideration (and not, for the avoidance of doubt, for purposes of financing any acquisition)
or equity securities issuable in connection with the Company’s stock option or other employee benefit plans, then the Company
shall deliver to the undersigned a written notice of such determination and, if within fifteen (15) days after the date of the
delivery of such notice, the undersigned shall so request in writing, the Company shall include in such Piggyback Registration
Statement all or any part of such Shares and Warrant Shares the undersigned requests to be registered. If a Piggyback Registration
Statement covering the Shares and Warrants Shares has not been filed and declared effective by the date that is 180 days after
the date of this Subscription Agreement, then, at the request of the undersigned, the Company shall prepare and file with the Commission
a registration statement covering the Shares and Warrant Shares (a “Demand Registration Statement” and together
with a Piggyback Registration Statement, a “Registration Statement”) and shall use its best efforts to cause
such Demand Registration Statement to be declared effective by the Commission as soon as practicable thereafter. In the case that
any Registration Statement is filed in connection with an underwritten offering, and the managing underwriter advises the Company
in writing that in its opinion the number of shares of Common Stock proposed to be included in such registration, including all
Shares and Warrant Shares and all other shares of Common Stock proposed to be included in such underwritten offering, exceeds the
number of shares of Common Stock which can be sold in such offering and/or that the number of shares of Common Stock proposed to
be included in any such registration would adversely affect the price per share of the Common Stock to be sold in such offering,
then the Company shall reduce the number of Shares and Warrant Shares registered under such Registration Statement as so advised;
provided that the Company shall still be required to register the Shares and the Warrant shares on an additional registration statement
as provided in this Section 10.

 

11. Additional
Covenants.

 

(a) The
Company shall, on or before the Closing Date, take such action as the Company shall reasonably determine is necessary in order
to obtain an exemption for or to qualify the Securities for sale to the undersigned at the Closing pursuant to this Subscription
Agreement under applicable securities laws (or to obtain an exemption from such qualification), and shall provide evidence of any
such action so taken to the undersigned on or prior to the Closing Date. The Company shall make all filings and reports relating
to the offer and sale of the Securities required under applicable securities laws following the Closing Date.

 

    11

    

    

 

(b) The
Company shall promptly secure the listing of all of the Shares and, when issued, Warrant Shares upon each national securities exchange
and automated quotation system, if any, upon which the Common Stock is then listed (subject to official notice of issuance) and
shall maintain such listing. The Company shall maintain the authorization for quotation of the Common Stock on the Principal Market
or any other Trading Market (as defined in the Warrant Agreement). The Company shall not take any action which would be reasonably
expected to result in the delisting or suspension of the Common Stock on the Principal Market. The Company shall pay all fees and
expenses in connection with satisfying its obligations under this Section 11(b).

 

(c) So
long as the undersigned or any of its permitted transferees owns any Warrants, the Company shall take all action necessary to at
all times after the date hereof have authorized, and reserved for the purpose of issuance, no less than the number of shares of
Common Stock issuable upon exercise of the Warrants then outstanding.

 

(d) At
all times following the Closing Date, the Company shall fully comply with all current public information requirements of Rule 144
under the Securities Act.

 

12. Waiver,
Amendment. Neither this Subscription Agreement nor any provisions hereof shall be modified, changed, discharged or terminated
except by an instrument in writing, signed by the party against whom any waiver, change, discharge or termination is sought.

 

13. Assignability.
This Subscription Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns.
The Company shall not assign this Subscription Agreement or any rights or obligations hereunder without the prior written consent
of the undersigned. The undersigned may assign some or all of its rights hereunder without the consent of the Company, in which
event such assignee shall be deemed to be the undersigned hereunder with respect to such assigned rights.

 

14. Waiver
of Jury Trial. EACH OF THE UNDERSIGNED AND THE COMPANY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY WITH RESPECT TO
ANY LEGAL PROCEEDING ARISING OUT OF THE TRANSACTIONS CONTEMPLATED BY THIS SUBSCRIPTION AGREEMENT.

 

15. Submission
to Jurisdiction. With respect to any suit, action or proceeding relating to any offers, purchases or sales of the
Securities by the undersigned ("Proceedings"), each of the undersigned and the Company irrevocably submits
to the jurisdiction of the federal or state courts located in the Borough of Manhattan in New York City, which submission
shall be exclusive unless none of such courts has lawful jurisdiction over such Proceedings.

 

16. Governing
Law. This Subscription Agreement shall be governed by and construed in accordance with the laws of the State of New York.

 

    12

    

    

 

17. Section
and Other Headings. The section and other headings contained in this Subscription Agreement are for reference purposes only
and shall not affect the meaning or interpretation of this Subscription Agreement.

 

18. Counterparts.
This Subscription Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be
deemed to be an original and all of which together shall be deemed to be one and the same agreement.

 

19. Notices.
All notices and other communications provided for herein shall be in writing and shall be deemed to have been duly given if delivered
personally or sent by registered or certified mail, return receipt requested, postage prepaid to the following addresses (or such
other address as either party shall have specified by notice in writing to the other):

 

	 	If to the Company:	
        HealthLynked Corp.

1265 Creekside Parkway Suite 302

Naples,
        Florida 34108

         

        Facsimile: (239) 719-3434

         

        E-mail: goleary@healthlynked.com

         

        Attention:Chief Financial Officer

	 	 	 
	 	with a copy to:	
        K&L Gates LLP

        200 S. Biscayne Blvd. Suite 3900

        Miami, Fl
        33131

         

        Facsimile: (305) 358-7095

         

        E-mail: clayton.parker@klgates.com

         

        Attention: Clay Parker

	 	 	 
	 	If to the Purchaser:	
        Address:

         

        E-mail: Daniel.hall@krisdan.com

         

        Attention: Daniel Hall

 

    13

    

    

 

20. Binding
Effect. The provisions of this Subscription Agreement shall be binding upon and accrue to the benefit of the parties hereto
and their respective heirs, legal representatives, successors and assigns.

 

21. Entire
Agreement. This Subscription Agreement constitutes the entire agreement and supersedes all prior and contemporaneous agreements
and understandings among the parties with respect to the subject matter hereof and thereof.

 

22. Survival.
All representations, warranties and covenants contained in this Subscription Agreement shall survive (i) the acceptance of the
subscription by the Company and the Closing, (ii) changes in the transactions, documents and instruments described herein which
are not material or which are to the benefit of the undersigned and (iii) the death or disability of the undersigned.

 

23. Notification
of Changes. The undersigned hereby covenants and agrees to notify the Company upon the occurrence of any event prior to the
closing of the purchase of the Securities pursuant to this Subscription Agreement which would cause any representation, warranty,
or covenant of the undersigned contained in this Subscription Agreement to be false or incorrect.

 

24. Severability.
If any term or provision of this Subscription Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity,
illegality or unenforceability shall not affect any other term or provision of this Subscription Agreement or invalidate or render
unenforceable such term or provision in any other jurisdiction.

 

[SIGNATURE PAGE FOLLOWS]

 

    14

    

    

 

IN WITNESS WHEREOF, the undersigned has executed
this Subscription Agreement this 26th day of February 2021.

 

	PURCHASER (if an individual):	 	PURCHASER (if an entity):

 

	By	 	 	DanKris1, LLC 
	Name:	 	 	Legal Name of Entity

 

	SS# 	 	 

	 	By	 
	 	Name:  	 
	 	Title:  	 

 

	By:	 	 
	Name:	 	 

 

	SS#	 	 

	 	FEIN #:	 

 

State/Country of Domicile or Formation:

Aggregate Subscription Amount: US$2,000,000 Two
Million Dollars

 

The offer to purchase
Securities as set forth above is confirmed and accepted by the Company as to 7,692,308 shares of Common Stock and warrants to
purchase 3,846,154 shares of Common Stock.

 

	 	HEALTHLYNKED CORP.

 

	 	By:	 
	 	Name:	George G. O’Leary
	 	Title:	Chief Financial Officer

 

    15

    

    

 

APPENDIX
A

 

Consideration
To Be Delivered

 

	Securities to Be Acquired	 	Aggregate Purchase Price to be Paid	 
	7,692,308 shares of Common Stock and warrants to purchase 3,846,154 shares of Common Stock	 	US$	2,000,000	 

 

 

16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]